Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 11:14:1213916.
doi: 10.3389/fgene.2023.1213916. eCollection 2023.

Advances in genetic variation in metabolism-related fatty liver disease

Fan Shi  1 , Mei Zhao  1 , Shudan Zheng  1 , Lihong Zheng  2 , Haiqiang Wang  3
Affiliations
Review

Advances in genetic variation in metabolism-related fatty liver disease

Fan Shi et al. Front Genet. .

Abstract

Metabolism-related fatty liver disease (MAFLD) is the most common form of chronic liver disease in the world. Its pathogenesis is influenced by both environmental and genetic factors. With the upgrading of gene screening methods and the development of human genome project, whole genome scanning has been widely used to screen genes related to MAFLD, and more and more genetic variation factors related to MAFLD susceptibility have been discovered. There are genetic variants that are highly correlated with the occurrence and development of MAFLD, and there are genetic variants that are protective of MAFLD. These genetic variants affect the development of MAFLD by influencing lipid metabolism and insulin resistance. Therefore, in-depth analysis of different mechanisms of genetic variation and targeting of specific genetic variation genes may provide a new idea for the early prediction and diagnosis of diseases and individualized precision therapy, which may be a promising strategy for the treatment of MAFLD.

Keywords: HSD17B13; MAFLD; PNPLA3; genetic variation; therapeutic potential.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Schematic diagram of pathogenesis of genetic variation of PNPLA3 I148M.
FIGURE 2
FIGURE 2
Molecular mechanism of genetic variation in MAFLD.
See this image and copyright information in PMC

References

    1. Abul-Husn N. S., Cheng X., Li A. H., Xin Y., Schurmann C., Stevis P., et al. (2018). A protein-truncating HSD17B13 variant and protection from chronic liver disease. N. Engl. J. Med. 378, 1096–1106. 10.1056/NEJMoa1712191 - DOI - PMC - PubMed
    1. Akkiz H., Taskin E., Karaogullarindan U., Delik A., Kuran S., andKutlu O. (2021). The influence of RS738409 I148M polymorphism of patatin-like phospholipase domain containing 3 gene on the susceptibility of non-alcoholic fatty liver disease. Med. Baltim. 100, e25893. 10.1097/MD.0000000000025893 - DOI - PMC - PubMed
    1. Banini B. A., Kumar D. P., Cazanave S., Seneshaw M., Mirshahi F., Santhekadur P. K., et al. (2021). Identification of a metabolic, transcriptomic, and molecular signature of patatin-like phospholipase domain containing 3-mediated acceleration of steatohepatitis. Hepatol. Baltim. Md 73, 1290–1306. 10.1002/hep.31609 - DOI - PMC - PubMed
    1. Basu Ray S. (2019). PNPLA3-I148M: a problem of plenty in non-alcoholic fatty liver disease. Adipocyte 8, 201–208. 10.1080/21623945.2019.1607423 - DOI - PMC - PubMed
    1. Basuray S., Smagris E., Cohen J. C., andHobbs H. H. (2017). The PNPLA3 variant associated with fatty liver disease (I148M) accumulates on lipid droplets by evading ubiquitylation. Hepatology 66, 1111–1124. 10.1002/hep.29273 - DOI - PMC - PubMed

LinkOut - more resources